CD163 and neoplasm: Profiling was performed with multiple CyCIF panels to enable discrimination of tumor differentiation states (e.g., SOX10, MART1, PMEL, and NGFR), proliferation (KI67, PCNA, and phospho-histone H3 (pH3)), apoptosis (cleaved caspase 3 (cCC3) and cPARP1), stromal structures (CD31 and αSMA), as well as immune lineages (e.g., CD45, CD3E, CD8A, CD4, FOXP3, CD20, CD11C, CD68, and CD163), and their activity states (e.g., PD1 and GZMB).